dMed and Clinipace Complete Merger to Accelerate Client Success and Global Innovation in Clinical Research

dMed—a full-service clinical contract research organization (CRO) headquartered in Shanghai, China—and Clinipace—a full-service clinical CRO headquartered in North Carolina, USA—today announced the formal completion of their merger. This merger will meet the rapidly growing needs of biotechnology, pharmaceutical, and medical device companies, and accelerate the delivery of innovative solutions to patients worldwide.

The merged company will have more than 1,600 employees across 22 countries. The new entity will become a highly differentiated mid-sized global clinical contract research organization (CRO), holding a competitive advantage in geographic coverage, service offerings, and therapeutic area expertise, positioning it on par with leading global CROs. Its service capabilities in North America, Asia-Pacific, Europe, and Latin America will directly compete with the world-class services provided by major leading contract research organizations (CROs).

Dr. Tan Lingshi, current Chairman and Chief Executive Officer of dMed, will serve as Chairman and Global Chief Executive Officer of the new company, while Mr. Jason Monteleone, current Chief Executive Officer of Clinipace, will serve as Chief Business and Strategy Officer of the new company.

Dr. Tan Lingshi provided a succinct summary of this opportunity, stating, “Amidst the fundamental shifts reshaping the landscape of global clinical trials, biotechnology companies worldwide are increasingly recognizing the need for a strategic partner that can help them maintain a competitive edge at the forefront of innovation. Meanwhile, China has emerged as one of the most critical markets globally, serving as a leading region for accelerating drug development and commercialization, as well as a hub fostering the rapid growth of innovative biotech firms that are aggressively pursuing globalization strategies. Following the merger, we will be better positioned to deliver comprehensive services to pharmaceutical innovators in both China and around the world.”

Mr. Monteleone added, “We look forward to helping innovative biotechnology companies, as well as small, medium, and even large pharmaceutical and medical device companies, enter the United States and China—the world’s two largest pharmaceutical and medical device markets—more quickly and smoothly. Through this strategic alliance, dMed and Clinipace will jointly provide advanced technologies, expertise, and a truly global network across multiple therapeutic areas, continuously empowering our clients to achieve remarkable success. Our new company will maintain its commitment to customized client services and innovative solutions, which have been hallmarks of dMed’s and Clinipace’s past successes.”

Founded in 2016 by Dr. Tan Lingshi, former Vice President of Global Clinical Operations at Pfizer and the first General Manager of Pfizer’s China R&D Center, dMed is a contract research organization (CRO) steered by a world-class elite team, providing comprehensive services in clinical development and regulatory affairs. Since its inception, dMed has been serving diverse clients, helping enterprises adapt to China’s evolving regulatory landscape, integrate their resources, and achieve rapid growth amid the accelerating internationalization of clinical trials. In 2019, dMed took its first step toward globalization by acquiring Target Health, a U.S.-based company.

Clinipace boasts nearly 25 years of extensive experience in clinical trials and regulatory affairs, along with specialized expertise in core therapeutic areas including oncology, nephrology, rare diseases, gastroenterology, and women’s health. The company has demonstrated outstanding performance globally and successfully established a broad network of strategic client partnerships.

dMed, founded in 2016, has grown to a team of nearly 700 professionals, with a presence in 31 cities across China and three offices in the United States. In this unprecedented era of pharmaceutical innovation, dMed is committed to becoming a next-generation, full-service clinical development partner, empowering clients to deliver innovative solutions to patients worldwide, particularly in the two largest healthcare markets: the United States and China. dMed’s U.S. operations also include Target Health, a full-service, technology-driven contract research organization (CRO) renowned for its expertise in digital capabilities and regulatory affairs.

Clinipace is a global full-service clinical research organization (CRO) that conducts clinical trials through a personalized approach. The highly collaborative and flexible services offered by Clinipace are unattainable within the environment of traditional contract research organizations. Emphasizing personalized services and solutions, Clinipace boasts leadership in clinical trial experience, regulatory affairs expertise, and therapeutic areas. Its mission is to continuously advance the conduct of clinical research in key therapeutic areas, including oncology, rare diseases, gastroenterology, nephrology, and women’s health.

For any further inquiries, please send an email to the following address:

dMed_news＠dmedglobal.com